Craif and Nagoya University Hospital Starts a Joint Study Aiming for Order Made Medicine for Ovarian Cancer and Other Gynecological Cancers

Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has entered into a new joint study agreement with Nagoya University Hospital (Location: Nagoya, Aichi, Hospital Director: Yasuhiro Kodera).

With the conclusion of this agreement, Craif will begin a joint study with the Department of Obstetrics and Gynecology at Nagoya University Graduate School of Medicine (Professor: Hiroaki Kajiyama, and Assistant Professor: Akira Yokoi) for order made medicine for gynecological cancer.

■ Outline of the Study
This research aims to clarify the molecular mechanisms underlying intractability of gynecological cancers (ovarian cancer, uterine cancer, and other rare cancers) by conducting omics analysis using next-generation sequencers for urinary miRNAs and proteome analysis using protein mass analyzers, etc. We will explore the possibility of new cancer diagnosis and treatment leading to order made medicine.